<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-86176</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Role of daptomycin in the empirical and directed therapy of infections caused by Grampositive bacteria in the critically ill patient</dc:title>
<dc:description xml:lang="en">Infections caused by Gram-positive bacteria are a serious problem and is associated with high mortality. Among them, we should highlight those caused by methicillin-resistant Staphylococcus aureus (MRSA). Primary bacteremia, catheterrelated bloodstream infections and constitute the main presentations. Vancomycin has traditionally been the treatment of choice for these infections, but its activity is not satisfactory especially in cases of MRSA with minimum inhibitory concentration (MIC) &gt; 1 mg/L. Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria including MRSA and glycopeptide-resistant Enterococcus spp. It is worth mentioning that daptomycin is rapidly bactericidal against methicillin-sensitive S. aureus, more potent than vancomycin and at least as active as isoxazole penicillins. This article discusses the role of this antibiotic in the empirical treatment of infections and directed by Gram-positive bacteria affecting critically ill patients(AU)</dc:description>
<dc:creator>Torre Prados, M. Victoria de la</dc:creator>
<dc:creator>Gómez-Grande, M. Luisa</dc:creator>
<dc:creator>Lorente-Ramos, Leonardo</dc:creator>
<dc:creator>Pomares Mora, José</dc:creator>
<dc:creator>Garnacho-Montero, José</dc:creator>
<dc:creator>Martínez Pellús, Antonio</dc:creator>
<dc:creator>Jerez Gómez-Coronado, Vicente</dc:creator>
<dc:creator>Loza Vázquez, Ana</dc:creator>
<dc:creator>Pozo Laderas, Juan Carlos</dc:creator>
<dc:creator>Ortiz Leyba, Carlos</dc:creator>
<dc:creator>Amaya-Villar, Rosario</dc:creator>
<dc:creator>Sierra Camerino, Rafael</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las infecciones graves causadas por bacterias grampositivas son un problema grave y que se asocia a una elevada mortalidad. Entre ellas, hay que resaltar las causadas por Staphylococcus aureus resistente a meticilina siendo la bacteriemia primaria o asociada a catéter o a endocarditis las principales presentaciones. Vancomicina ha sido tradicionalmente el tratamiento de elección para estas infecciones pero su actividad no es satisfactoria especialmente en caso de SARM con concentración mínima inhibitoria (CMI) &gt; 1mg/L. Daptomicina es un antibiótico lipopéptido cuyo espectro de acción son las bacterias grampositivas incluyendo SARM y Enterococcus spp resistente a glucopéptido. Destacar también que frente a S. aureus sensible a meticilina, daptomicina es rápidamente bactericida y más activo que vancomicina y al menos tan activo como las penicilinas isoxazólicas, En el presente artículo se discute el papel de este antibiótico en el tratamiento empírico y dirigido de las infecciones por bacterias grampositivas que afectan a los pacientes críticos(AU)</dc:description>
<dc:source>Rev Esp Quimioter;24(1): 13-24, mar.2011. tab, ilus</dc:source>
<dc:identifier>ibc-86176</dc:identifier>
<dc:title xml:lang="es">Papel de daptomicina en el tratamiento empírico y dirigido de infecciones por cocos grampositivos del paciente crítico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30345^s22021</dc:subject>
<dc:subject>^d30345^s22001</dc:subject>
<dc:subject>^d31518^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30241^s22057</dc:subject>
<dc:subject>^d30241^s22012</dc:subject>
<dc:subject>^d13596^s22001</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d13596^s22021</dc:subject>
<dc:subject>^d30068^s22021</dc:subject>
<dc:subject>^d31518^s22078</dc:subject>
<dc:subject>^d30068^s22001</dc:subject>
<dc:subject>^d30170</dc:subject>
<dc:subject>^d31518^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201103</dc:date>
</metadata>
</record>
</ibecs-document>
